Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 381

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 381
---
8 and founded Lone Mountain Biotechnology and Medical Devices Inc.,
a consulting company. Dr Garnick was co-founder of Bioanalytix in Boston and an early investor in Stemcentrx in San Francisco. Dr. Garnick
has extensive drug and biologics development experience and was a frequent lecturer on biotechnology products and processes.

The Board concluded that Dr. Garnick should serve
as a director because of his extensive drug development and commercialization experience with biotechnology products.

Paul Lytle. Mr. Lytle was nominated to serve
as a director on August 21, 2020, and was appointed Executive Vice President, Chief Financial Officer on August 31, 2020. Effective June
1, 2024, Mr. Lytle reduced his time commitment to part-time status to provide no more than 8 hours of service per month. Mr. Lytle has
over 25 years of finance and accounting experience, including over 20 years of public company experience and CFO experience in the field
of biotechnology and medical devices. Mr. Lytle currently serves as Chief Financial Officer of Actuate Therapeutics, Inc. since February
2024. Mr. Lytle previously served as Executive Vice President, Chief Financial Officer of Breathe Technologies, Inc. (“Breathe”),
a private venture-backed medical device company with an approved portable ventilator, from September 2018 to December 2019. Prior to Breathe,
Mr. Lytle served as Chief Financial Officer of Avid Bioservices, Inc. for 18 years, during which time the company advanced multiple products
in oncology and infectious diseases, while starting and expanding its biomanufacturing business to over $55 million in revenue. Prior
to joining Avid Bioservices, Mr. Lytle was employed by Deloitte.

The Board concluded that Mr. Lytle should serve as
a director because of his extensive experience with public companies in the biotechnology field along with his experience with product
development, corporate financing, mergers and acquisitions, and corporate governance.

 40 

Corporate
Governance

Meetings and Committees of the Board

We have three (3) standing committees of the Board,
consisting of the Audit Committee, the Compensation Committee, and the Corporate Governance and Nominating Committee. Our committees operate
under written charters adopted by the Board in November 2020, a copy of which is available on our website at www.mosaicie.com under the
Corporate Governance section of our Investors